文献速递冠心病血脂与心血管预防

心肺运动试验与经皮冠状动脉介入疗效:ORBITA试验亚组分析

Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究为ORBITA试验亚组分析,纳入195例严重单支冠状动脉疾病患者,随机接受PCI或安慰剂。结果显示,心肺运动试验中氧脉搏平台可检测心肌缺血严重程度,并预测PCI相对于安慰剂的疗效;而其他受损的CPET参数与症状负担相关,但与缺血严重程度或PCI反应无关。

要点

  • 氧脉搏平台与更严重的缺血(DSE评分更高、FFR更低)相关。
  • 氧脉搏平台存在及氧脉搏梯度可预测PCI对DSE评分的安慰剂对照效应。
  • 峰值VO2、VE/VCO2斜率等受损与症状负担相关,但不预测PCI反应。

核心结论

  • 在严重单支冠状动脉疾病患者中,氧脉搏平台可检测心肌缺血严重程度并预测PCI的安慰剂对照疗效。

研究设计与样本

  • ORBITA试验亚组分析,纳入195例有CPET数据的严重单支冠状动脉疾病患者,随机1:1接受PCI(102例)或安慰剂(93例)。
  • 受试者随机前接受平板CPET、多巴酚丁胺负荷超声心动图(DSE)和症状评估,并在6周盲法随访结束时重复评估。

主要发现

  • 观察到氧脉搏平台的患者DSE评分更高(更缺血)[+0.82节段;95%CI:0.40至1.25,P=0.0068],FFR更低(-0.07;95%CI:-0.12至-0.02,P=0.011)。
  • 氧脉搏斜率越低(越异常),PCI对DSE评分的安慰剂对照效应改善越大[氧脉搏平台存在(P交互=0.026)和氧脉搏梯度(P交互=0.023)]。
  • 氧脉搏平台存在时,PCI对西雅图心绞痛躯体受限评分的安慰剂对照效应改善更大(P交互=0.037)。
  • 峰值VO2、VE/VCO2斜率、峰值氧脉搏和氧摄取效率斜率受损与更高症状负担显著相关,但与缺血严重程度无关,也不预测PCI反应。

临床怎么用

  • 心肺运动试验中氧脉搏平台可用于识别可能从PCI获益的严重单支冠状动脉疾病患者。
  • 其他CPET参数(峰值VO2、VE/VCO2斜率等)反映症状负担,但不应用于预测PCI疗效。

局限性

  • 本研究为ORBITA试验亚组分析,样本量有限(195例),结果需在更广泛人群中验证。
  • 研究仅纳入严重单支冠状动脉疾病患者,结论不适用于多支病变或其他人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Oxygen-pulse morphology and gas exchange analysis measured during cardiopulmonary exercise testing (CPET) has been associated with myocardial ischaemia. The aim of this analysis was to examine the relationship between CPET parameters, myocardial ischaemia and anginal symptoms in patients with chronic coronary syndrome and to determine the ability of these parameters to predict the placebo-controlled response to percutaneous coronary intervention (PCI). METHODS AND RESULTS: Patients with severe single-vessel coronary artery disease (CAD) were randomized 1:1 to PCI or placebo in the ORBITA trial. Subjects underwent pre-randomization treadmill CPET, dobutamine stress echocardiography (DSE) and symptom assessment. These assessments were repeated at the end of a 6-week blinded follow-up period.A total of 195 patients with CPET data were randomized (102 PCI, 93 placebo). Patients in whom an oxygen-pulse plateau was observed during CPET had higher (more ischaemic) DSE score [+0.82 segments; 95% confidence interval (CI): 0.40 to 1.25, P = 0.0068] and lower fractional flow reserve (-0.07; 95% CI: -0.12 to -0.02, P = 0.011) compared with those without. At lower (more abnormal) oxygen-pulse slopes, there was a larger improvement of the placebo-controlled effect of PCI on DSE score [oxygen-pulse plateau presence (Pinteraction = 0.026) and oxygen-pulse gradient (Pinteraction = 0.023)] and Seattle angina physical-limitation score [oxygen-pulse plateau presence (Pinteraction = 0.037)]. Impaired peak VO2, VE/VCO2 slope, peak oxygen-pulse, and oxygen uptake efficacy slope was significantly associated with higher symptom burden but did not relate to severity of ischaemia or predict response to PCI. CONCLUSION: Although selected CPET parameters relate to severity of angina symptoms and quality of life, only an oxygen-pulse plateau detects the severity of myocardial ischaemia and predicts the placebo-controlled efficacy of PCI in patients with single-vessel CAD.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ganesananthan S, Rajkumar CA, Foley M, et al. Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial. Eur Heart J. 2022. PMID: 35639660. doi:10.1093/eurheartj/ehac260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。